Loading...
•
Mar 31
Precipio Q1 2025 Earnings Report
Reported strong year-over-year revenue growth with improved margins and reduced operating expenses.
Key Takeaways
Precipio delivered a 43% YoY revenue increase in Q1 2025, driven by gains in both its Products and Pathology Services divisions. Gross margins improved substantially, and adjusted EBITDA showed significant progress toward profitability, reflecting better cost control and operational efficiency.
Revenue reached $4,900,000, up 43% YoY despite a seasonal dip from Q4.
Gross margin rose to 43%, driven by improvements across both divisions.
Adjusted EBITDA improved to a loss of $108,000, down from $1,409,000 loss YoY.
Net cash used in Q1 operations declined to $372,000, a 49% improvement YoY.
Precipio
Precipio
Forward Guidance
Management expects to return to positive operating cash flow by Q2 or Q3 and sees 2025 as a transformative year for scalable growth and improved margins.
Positive Outlook
- Expected return to positive cash flow from operations by Q2/Q3
- Product revenue growth anticipated as pipeline strengthens
- MolDx approval enables Medicare billing for NGS testing
- Gross margins expected to continue improving
- Adequate cash reserves to support operations throughout 2025
Challenges Ahead
- Seasonal slowdown in pathology revenue in Q1
- Temporary customer onboarding delays affected product sales
- No clear net income reported for Q1
- Cash flow still negative in Q1 despite improvements
- Gross profit and revenue per segment figures not fully disclosed